Amgen (AMGN): FY26 Q1 earnings call, Apr 30, 2026
No Kalshi or Polymarket word markets were listed for Amgen’s Apr 30, 2026 earnings call (FY26 Q1). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
4 matches for “Tavneos”; 2 quoted, at least 25 words apart.
…2025, we expect additional global launches of TEPEZZA in 2026 and beyond. TAVNEOS sales were $119 million in the first quarter, up 32% year-over-year, driven…
…year. As publicly disclosed, the FDA proposed to withdraw the approval of TAVNEOS. We continue to believe that TAVNEOS is an important medicine for patients…
Agents: this page as TSV at /api/v1/appearances/amgen:2026-04-30:earnings_call · words: /api/v1/brief?appearance=amgen:2026-04-30:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP